Experimental fusion protein aims to re-engage immune system against tough esophageal cancer
NCT ID NCT07688291
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This phase 2 trial tests a single drug called PD-1/IL-2α-bias bispecific antibody fusion protein in people with advanced or metastatic esophageal squamous cell carcinoma whose cancer worsened after prior immunotherapy and chemotherapy. The drug is designed to boost the immune system's ability to attack cancer cells. The study will measure how many patients respond, how long they live, and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-1/IL-2α-bias bispecific antibody fusion protein
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced esophageal cancer who have run out of standard therapies.
- What could go wrong
- This is an early phase 2 trial with only 40 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CARCINOMA CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102206, China